Pioneering new immunoassays for inhibin A and B, developed by Professor Nigel Groome at Oxford Brookes University, have contributed to a significant improvement in the accuracy of pre-natal screening for Downs Syndrome. Use of inhibin A in the ‘Quad’ and ‘integrated’ tests, protected by international patents, is widespread in the US (c.3million screened annually) and was recommended by the NHS in 2010, leading to a significant increase in the use of the assays (c.120,000 annually) in the UK. They are also used in clinical diagnostic and monitoring applications for male and female infertility, abnormalities in sexual development in children and ovarian granulosa tumours. Commercialisation has led to royalty income to Brookes from sales which totalled approximately c.£5million in the period January 2008 to December 2012, indicative of the c.US$135million earned in worldwide sales in the same period.
(Oxford Brookes University)
Faculty of Health and Life Sciences
Year of publication: 2013Date of RADAR deposit: 2014-12-18
Oxford Brookes University
Published by Oxford Brookes University